Study of FYU-981 in Hyperuricemia (Effect on Two Hyperuricemic Types)

Seven-day Repeated Dose Clinical Pharmacological Study of FYU-981 Administered to Hyperuricemia

To investigate the pharmacodynamics, pharmacokinetics and safety of 7-day-repeated doses of FYU-981 administered orally to male hyperuricemic patients with uric acid-overproduction or uric acid-underexcretion type.

In addition, to investigate the additive effects of the combination of FYU-981 and topiroxostat administered orally to male hyperuricemic patients with uric acid-overproduction type.

Inclusion Criteria:

• Japanese adult subjects
• Serum urate level: >= 7.0mg/dL in patients
• Disease Type: Uric acid-overproduction Type or Uric acid-underexcretion Type

Exclusion Criteria:

• Gouty arthritis within a year before start of study treatment
• Mixed type in the classification of hyperuricemia